Skip to main content
SpringerLink
Log in

Effects of calcitonin on knee osteoarthritis and quality of life

  • Original Article
  • Published:
Rheumatology International Aims and scope Submit manuscript

Abstract

There has been a recent interest in calcitonin as a potential treatment for osteoarthritis, based on its metabolic activities in both bone turnover and cartilage. The aim of this study was to evaluate the effects of nasal form calcitonin on knee osteoarthritis and quality of life in women who receive calcitonin treatment for postmenopausal osteoporosis. Two hundred and twenty postmenopausal women, aged between 55 and 65 years with knee pain and knee osteoarthritis, graded II–III by using Kellgren–Lawrence radiographic scoring system, were included. Western Ontario and McMaster Universities (WOMAC) osteoarthritis index, the quality of life questionnaire of the European Foundation for Osteoporosis (QALEFFO-41) and visual analog scale were used for the algofunctional assessments. Need of rescue analgesic was recorded. Pain (P < 0.001), stiffness (P < 0.05), functional capability (P < 0.05) and total score of WOMAC (P < 0.05) revealed statistically significant improvements after 3 months of the treatment and remained consistent throughout 1 year of the treatment period. Participants experienced significant reductions in WOMAC perceptions of pain (−53 %), joint stiffness (−44 %) and limitations in physical function (−49 %) at the end of 1 year of calcitonin treatment. Need of rescue analgesic intake was reported to have decreased approximately by 60 % at the end of the 1-year treatment period. QUALEFFO_41 scores improved: 37.6 (baseline), 30.9 (3 months), 28.0 (6 months) and 24.4 (1 year). In conclusion, nasal calcitonin treatment provided dual action on osteoporosis and osteoarthritis with significant improvements in quality of life and algofunctional results in knee osteoarthritis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Abramson SB, Honig S (2007) Antiresorptive agents and osteoarthritis: more than a bone to pick? Arthritis Rheum 56(8):2469–2473

    Article  PubMed  CAS  Google Scholar 

  2. Krasnokutsky S, Samuels J, Abramson SB (2007) Osteoarthritis in 2007. Bull NYU Hosp Jt Dis 65(3):222–228

    PubMed  Google Scholar 

  3. Felson DT, Neogi T (2004) Osteoarthritis: is it a disease of cartilage or of bone? Arthritis Rheum 50:341–344

    Article  PubMed  Google Scholar 

  4. Karsdal MA, Leeming DJ, Dam EB, Henriksen K, Alexandersen P, Pastoureau P et al (2008) Should subchondral bone turnover be targeted when treating osteoarthritis? Osteoarthr Cartil 16:638–646

    Article  PubMed  CAS  Google Scholar 

  5. Davis MA, Ettinger WH, Nuhaus JM (1991) Knee osteoarthritis and physical functioning: evidence from the NHANES 1 epidemiologic follow up study. J Rheumatol 18:591–598

    PubMed  CAS  Google Scholar 

  6. Hopman-Rock M, Oddind E, Hofman A (1996) Physical and psychological disability in elderly subjects in relation to pain in the hip and/or knee. J Rheumatol 23:1037–1044

    PubMed  CAS  Google Scholar 

  7. Zimmermann M (1989) Pain mechanisms and mediators in osteoarthritis. Semin Arthritis Rheum 18:51–56

    Article  Google Scholar 

  8. Chambers TJ, Moore A (1983) The sensitivity of isolated osteoclasts to morphological transformation by calcitonin. J Clin Endocrinol Metab 57:379–385

    Article  Google Scholar 

  9. Karsdal MA, Tanko LB, Riis BJ, Sondergard BC et al (2006) Calcitonin is involved in cartilage homeostasis: is calcitonin a treatment for OA? Osteoarthr Cartil 14:617–624

    Article  PubMed  CAS  Google Scholar 

  10. Karsdal MA, Sondergaard BC, Arnold M, Chistiansen C (2007) Calcitonin affects both bone and cartilage: a dual action treatment for osteoarthritis? Ann NY Acad Sci 1117:181–195

    Article  PubMed  CAS  Google Scholar 

  11. Sondergaard BC, Ostergaard S, Christiansen C, Karsdal MA (2007) The effect of oral calcitonin on cartilage turn overhand surface erosion in the ovariectomized rat model. Arthritis Rheum 2007:2674–2678

    Article  Google Scholar 

  12. El Hajjaji H, Williams JM, Devogelaer JP, Lenz ME, Thonar EJ, Manicourt DH (2004) Treatment with calcitonin prevents the net loss of collagen, hyaluronan and proteoglycan aggregates from cartilage in the early stages of canine experimental osteoarthritis. Osteoarthr Cartil 12:904–911

    Article  PubMed  Google Scholar 

  13. Hannan MT, Felson DT, Anderson JJ, Naimark A, Kannel WB (1990) Estrogen use and radiographic osteoarthritis of the knee in women: the Framingham Osteoarthritis Study. Arthritis Rheum 33:525–532

    Article  PubMed  CAS  Google Scholar 

  14. Tüzün EH, Eker L, Aytar A, Daşkapan A, Bayramoğlu M (2005) Acceptability, reliability, validity and responsiveness of the Turkish version of WOMAC osteoarthritis index. Osteoarthr Cartil 13(1):28–33

    Article  PubMed  Google Scholar 

  15. Koçyigit H, Gülseren Ş, Erol A, Hizli N, Memis A (2003) The reliability and validity of the Turkish version of quality of life questionnaire of the European foundation for osteoporosis (QUALEFFO). Clin Rheumatol 22(1):18–23

    Article  PubMed  Google Scholar 

  16. Abramson SB, Attur M, Yazici Y (2006) Prospects for disease modification in osteoarthritis. Nat Clin Pract Rheumatol 2:304–312

    Article  PubMed  CAS  Google Scholar 

  17. Bingham CO, Buckland-Wright JC, Garnera P et al (2006) Risedronate decreases biomechanical markers of cartilage degradation but does not decrease symptoms or slow X-ray progression in patients with medial compartment osteoarthritis of the knee: results of 2 year multinational knee OA structural arthritis (KOSTAR) study. Arthritis Rheum 54:3494–3507

    Article  PubMed  CAS  Google Scholar 

  18. Karsdal MA, Byrjalsen I, Bay-Jensen AC, Henriksen K, Riis BJ, Christiansen C (2010) Biochemical markers identify influences on bone and cartilage degradation in osteoarthritis—the effect of sex, Kellgren–Lawrence (KL) score, body mass index (BMI), oral salmon calcitonin (sCT) treatment and diurnal variation. BMC Musculoskelet Disord 11:125

    Article  PubMed  CAS  Google Scholar 

  19. Sexton PM, Findlay DM, Martin TJ (1999) Calcitonin. Curr Med Chem 6:1067–1093

    PubMed  CAS  Google Scholar 

  20. Manicourt DH, Devogelaer JP, Azria M, Silverman S (2005) Rationale for the potential use of calcitonin in osteoarthritis. J Muskuloskelet Neuronal Interact 5:285–293

    CAS  Google Scholar 

  21. Martin TJ, Haris GS, Melick RA, Fraser JR (1969) Effect of calcitonin on glycosaminoglycan synthesis by embryo calf bone cells in vitro. Experientia 25:375–376

    Article  PubMed  CAS  Google Scholar 

  22. Baxter E, Fraser JR, Harris GS, Martin TJ, Melick RA (1968) Stimulation of glycosaminoglycan synthesis by thyrocalcitonin preparations. Med J Aust 1:216–217

    PubMed  CAS  Google Scholar 

  23. Franchimont P, Basleer C, Henrotin Y, Gysen P, Basleer R (1989) Effects of human and salmon calcitonin on human articular chondrocytes cultivated in clusters. J Clin Endocrinol Metab 69:259–266

    Article  PubMed  CAS  Google Scholar 

  24. Azria M (1989) The calcitonins (physiology and pharmacology). Karger, Basel

    Google Scholar 

  25. Lyritis GP, Trovas G (2002) Analgesic effects of calcitonin. Bone 30:715–745

    Article  Google Scholar 

  26. Plosker GL, McTavish D (1996) Intranasal salcatonin (salmon calcitonin). A review of its pharmacological properties and role in the management of postmenopausal osteoporosis. Drugs Aging 8:378–400

    Article  PubMed  CAS  Google Scholar 

  27. Sondergaard BS, Olsen AK, Sumer EU, Quvist P, Bagger YZ, Tanko LB et al (2005) Calcitonin stimulates proteoglycan and collagen type I1 biosynthesis in articular cartilage ex vivo. Osteoarthr Cartil 13(Suppl A):142

    Google Scholar 

  28. Sondergaard BC, Wulf H, Henrikksen K, Schaller S, Oestergaard S, Qvist P et al (2006) Calcitonin directly attenuates collagen type II degradation by inhibition of matrix metalloproteinase expression. Osteoarthr Cartil 14(8):759–768

    Article  PubMed  CAS  Google Scholar 

  29. Helio MP, Peschard MJ, Cohen C, Richard M, Vignon E (1997) Calcitonin inhibits phospholipase A2 and collagenase activity of human osteoarthritic chondrocytes. Osteoarthr Cartil 5:121–128

    Article  Google Scholar 

  30. Hoegh-Andersen P, Tanko LB, Andersen TL, Lundberg CV, Mo JA, Heegaard AM et al (2004) Ovariectomized rats as model of postmenopausal osteoarthritis: validation and application. Arthritis Res Ther 6:169–180

    Article  Google Scholar 

  31. Tanko LB, Bagger YZ, Alexandersen P, Devogelaer JP, Reginster JY, Chick R et al (2004) Safety and efficacy of a novel salmon calcitonin (sCT) technology-based oral formulation in healthy postmenopausal women: acute and 3-month effects on biomarkers of bone turnover. J Bone Miner Res 19:1531–1538

    Article  PubMed  CAS  Google Scholar 

  32. Bagger YZ, Tanko LB, Alexandersen P, Karsdal MA, Olson M, Mindeholm L et al (2005) Oral salmon calcitonin induced suppression of urinary collagen type II degradation in postmenopausal women: a new potential treatment of osteoarthritis. Bone 37:425–430

    Article  PubMed  CAS  Google Scholar 

  33. Manicourt DH, Azria M, Mindeholm L, Thonar EJ, Devogelaer JP (2006) Oral salmon calcitonin reduces Lequesne’s algofunctional index scores and decreases urinary and serum levels of biomarkers of joint metabolism in knee osteoarthritis. Arthritis Rheum 54(10):3205–3211

    Article  PubMed  CAS  Google Scholar 

  34. Manicourt DH, Azria M, Mindeholm L, Devogelaer JP (2005) Efficacy of calcitonin therapy in patients with knee osteoarthritis: a clinical and biochemical preliminary study. Osteoarthr Cartil 13:88

    Google Scholar 

Download references

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. Physical Medicine and Rehabilitation Department, Göztepe Training and Research Hospital, Medeniyet University, Istanbul, Turkey

    Meltem Esenyel & Afitap İçağasıoğlu

  2. Department of Orthopedics and Traumatology, Okmeydanı Training and Research Hospital, Istanbul, Turkey

    Cem Zeki Esenyel

Authors
  1. Meltem Esenyel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Afitap İçağasıoğlu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Cem Zeki Esenyel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Meltem Esenyel.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Esenyel, M., İçağasıoğlu, A. & Esenyel, C.Z. Effects of calcitonin on knee osteoarthritis and quality of life. Rheumatol Int 33, 423–427 (2013). https://doi.org/10.1007/s00296-012-2399-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00296-012-2399-z

Keywords

Search

Navigation